Referanslar

1. Ferlay J, Colombet m, soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144,1941-53. [Crossref]  [PubMed]
2. www.seer.cancer.gov/statfacts/html/esoph. html accessed on sep 12th, 2019.
3. Bollschweiler E, plum p, mönig sp, Hölscher AH. Current and future treatment options for esophageal cancer in the elderly. Expert Opin pharmacother. 2017;18(10):1001-10. [Crossref]  [PubMed]
4. Cummings LC, Kou TD, schluchter mD, Chak A, Cooper Gs. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. Gastrointest Endosc. 2016;84(2):232-40. [Crossref]  [PubMed]  [PMC]
5. Hölscher AH, Bollschweiler E, schroder W, metzger R, Gutschow C, Drebber u. prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Annals of surgery 2011;254(5):802-7;discussion 807-808. [Crossref]  [PubMed]
6. Medical Research Council Oesophageal Cancer Working Group. surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727-33. [Crossref]  [PubMed]
7. Al-Batran sE, pauligk C, Homann N et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer 2013 ;49(4), 835- 842. [Crossref]  [PubMed]
8. Tepper J, Krasna mJ, Niedzwiecki D et al. phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26 (7):1086-92. [Crossref]  [PubMed]  [PMC]
9. Shapiro J, van Lanschot JJ, Hulshof mC et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROss): long-term results of a randomised controlled trial. The Lancet. Oncology. 2015;16(9):1090-8.
10. Stahl m, Walz mK, stuschke m et al. phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27(6):851-6. [Crossref]  [PubMed]
11. Burmeister BH, Thomas Jm, Burmeister EA et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47(3):354-60. [Crossref]  [PubMed]
12. Klevebro F, Alexandersson von Dobeln G, Wang N et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660-7. [Crossref]  [PubMed]
13. Favi F, Bollschweiler E, Berlth F, et al. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J surg Oncol. 2017; 43 (8):1572-80. [Crossref]  [PubMed]
14. Minsky BD, pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94- 05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-74. [Crossref]  [PubMed]
15. Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97. [Crossref]  [PubMed]
16. NCCN v2 2019. Esophageal and esophagogastric junction cancers. ms-29-32. accessed on sep 14th, 2019. [Link]
17. Al-Batran s-E, Hartmann JT, probst s, et al. phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42. [Crossref]  [PubMed]
18. Okines AFC, Norman AR, mcCloud p, et al. meta-analysis of the REAL-2 and mL17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracilbased combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-34. [Crossref]  [PubMed]
19. Guimbaud R, Louvet C, Ries p, et al. prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520-6. [Crossref]  [PubMed]
20. van Cutsem E, moiseyenko vm, Tjulandin s, et al. phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study Group. J Clin Oncol. 2006;24:4991-7. [Crossref]  [PubMed]
21. shah mA, Janjigian YY, stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the us Gastric Cancer Consortium. J Clin Oncol. 2015;33:3874-9. [Crossref]  [PubMed]
22. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5Fu versus epirubicin, cisplatin and 5Fu for locally advanced gastric cancer. J Clin Oncol. 2005;23:4014. [Crossref]
23. Keskin s, Yıldız I, sen F, Aydogan F, Kilic L, Ekenel m, et al. modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol. 2013;15(5):403-88. [Crossref]  [PubMed]
24. Wilke H, muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-35. [Crossref]  [PubMed]
25. Accessed February 21, 2019. [Link]
26. Le DT, Durham JN, smith KN, et al. mismatch repair deficiency predicts response of solid tumors to pD-1 blockade. science 2017;357: 409-13. [Crossref]  [PubMed]  [PMC]
27. Kojima T, muro K, Francois E, et al. pembrolizumab versus chemotherapy as secondline therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol 2019;37:2. [Crossref]
28. Cunningham D, Allum WH, stenning sp, Thompson JN, van de velde CJ, Nicolson m, et al. perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J med. 2006;355(1):11-20. [Crossref]  [PubMed]
29. Lorenzen s, pauligk C, Homann N, schmalenberg H, Jager E, Al-Batran s-E. Feasibility of perioperative chemotherapy with infusional 5- Fu, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaksel in elderly patients with locally advanced esophagogastric cancer . Br J Cancer. 2013;108(3):519-26. [Crossref]  [PubMed]  [PMC]
30. Bang YJ, Kim YW, Yang HK, Chung HC, park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLAssIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379 (9813):315-21. [Crossref]  [PubMed]
31. Noh sH, park sR, Yang HK, Chung HC, Chung IJ, Kim sW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy ( CLAssIC ) : 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-96. [Crossref]  [PubMed]
32. Jin Y, Qiu mZ, Wang Ds, Zhang Ds, Ren C, Bai L, et al. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. pLos One. 2013;8(1):e53149. [Crossref]  [PubMed]  [PMC]
33. Sakuramoto s, sasako m, Yamaguchi T, Kinoshita T, Fujii m, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with s1, an oral fluoropyrimidine . N Engl J med. 2007; 357:1810-20. [Crossref]  [PubMed]
34. Cascinu s, Catalano G. Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubucin, 6s-leucovorin and glutathione with the support of G-CsF. Tumori. 1995;81:32-5. [Crossref]  [PubMed]
35. Trumper m, Ross pJ, Cunningham D, Norman AR, Hawkins R, seymour m, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials . Eur J Cancer may. 2006;42(7):827-34. [Crossref]  [PubMed]
36. Jatoi A, Foster NR, Egner JR, Burch pA, stella pJ, Rubin J, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive north central cancer treatment group (NCCTG) trials. Int J Oncol mar. 2010;36(3): 601-6. [Crossref]  [PubMed]  [PMC]
37. Wagner AD, unverzagt s, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database syst Rev. 2010;(3):CD 004064. [Crossref]
38. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, et al. A randomised multicentre phase II trial of capecitabine vs s-1 as firstline treatment in elderly patients with metastatic or recurrent unresectable gastric cancer .Br J Cancer. 2008;99(4):584-90. [Crossref]  [PubMed]  [PMC]
39. Koizumi W, Akiya T, sato A, sakuyama T, sasaki E, Tomidokoro T, et al. phase II study of s-1 as first-line teatment for elderly patients over 75 years of age with advanced gastric cancer : the Tokyo Cooperative Oncology Group study. Cancer Chemot her pharmacol. 2010;65(6):1093-9. [Crossref]  [PubMed]
40. petrioli R, pascuci A, Francini E, marsili s, Fiaschi AI, Civitelli s, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectastal and gastric cancer: a study of the multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008;19(1):91-6. [Crossref]  [PubMed]
41. Choi I, Lee K, Oh D, et al. Oxaliplatin , 5-fluorouracil, and folic acid as first-line chemoterapy for elderly patients with advanced gastric cancer. J Clin Oncol. 2006;24(18s):14155. [Crossref]
42. Liu ZF, Guo Qs, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol .2008;31:259-63. [Crossref]  [PubMed]
43. Catalona v, Bisonni R, Graziano F, Giordani p, Alessandroni p, Baldelli Am, et al. A phase II study of modifed FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013;16(3):411-9. [Crossref]  [PubMed]
44. Hwang IG, Ji JH, Kang JH, Lee HR, Lee H-Y, Chi K-C, et al. A multi-center, open label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer . J Geriatr Oncol may. 2017;8(3):170-5. [Crossref]  [PubMed]
45. Cunningham D, starling N, Rao s, Iveson T, Nicolson m, Coxon F, et al. upper Gastrointestinal Clinical studies Group of the National Cancer Resarch Institute of the united Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J med. 2008;358(1):36-46. [Crossref]  [PubMed]
46. van Cutsem E, moiseyenko vm, Tjulandin s, majilis A, Constenla m, Boni C, et al. phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the v325 study Group. J Clin Oncol. 2006;24:4991-4997. [Crossref]  [PubMed]
47. Diaz LA, uram JN, Wang H, Barlett B, Kemberling H, Eyring A. programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. J Clin Oncol .2016;34(suppl):abstr 3003. [Crossref]
48. Fuchs Cs, Doi T, Jang RW, et al. safety and Efficacy of pembrolizumab monotherapy in patients With previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: phase 2 Clinical KEYNOTE-059 Trial. JAmA Oncol. 2018;4(5):e180013.
49. Bang YJ, Kang YK, Catenacci Dv, et al. pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828-37. [Crossref]  [PubMed]  [PMC]
50. Shitara K, Özgüroğlu m, Bang YJ, et al. pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-33. [Crossref]  [PubMed]
51. Hurria A, Dale W, mooney m, et al. Designing therapeutic clinical trials for older and frail adults with cancer: u13 conference recommendations. J Clin Oncol. 2014;20;32(24): 2587-94. [Crossref]  [PubMed]  [PMC]
52. NCCN Older Adult Oncology 2016 v2. [Link]
53. sargent DJ, Goldberg Rm, Jacobson sD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J med. 2001;345(15):1091-7. [Crossref]  [PubMed]
54. Twelves C, Wong A, Nowacki mp, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J med. 2005;352(26): 2696-704. [Crossref]  [PubMed]
55. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter International study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353-60. [Crossref]  [PubMed]
56. Yothers G, O'Connell mJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NsABp C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768-74. [Crossref]  [PubMed]  [PMC]
57. Schmoll HJ, Cartwright T, Tabernero J, et al. phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25(1):102-9. [Crossref]  [PubMed]
58. EsmO Handbook of Cancer in senior patient. 2nd Edition. 2015.
59. Folprecht G, Cunningham D, Ross p, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330-8. [Crossref]  [PubMed]
60. Seymour mT, Thompson LC, Wasan Hs, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (mRC FOCus2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749-59. [Crossref]  [PubMed]
61. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International society of Geriatric Oncology (sIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463-76. [Crossref]  [PubMed]
62. Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31(11):1464-70. [Crossref]  [PubMed]
63. price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG mAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and mitomycin C. Ann Oncol. 2012;23(6):1531-6. [Crossref]  [PubMed]
64. Cunningham D, Lang I, marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AvEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077-85. [Crossref]  [PubMed]
65. Fornaro L, Baldi GG, masi G, et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAs and BRAF mutational status. Crit Rev Oncol Hematol. 2011;78(3):243-51. [Crossref]  [PubMed]
66. sastre J, Aranda E, Gravalos C, et al. Firstline single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011;77(1): 78-84. [Crossref]  [PubMed]
67. Pietrantonio F, Cremolini C, Aprile G, et al. single-agent panitumumab in frail elderly patients with advanced RAs and BRAF wildetype colorectal cancer: challenging drug label to light up new hope. Oncologist 2015;20(11): 1261-5. [Crossref]  [PubMed]  [PMC]
68. Yan m, Ha J, Aguilar m, et al. Older patients with hepatocellular carcinoma have more advanced disease, lower rates of treatment, and lower survival. J Clin Gastroenterol 2017;51: 378-83. [Crossref]  [PubMed]
69. Ziogas DC, papadatos-pastos D, Thillai K, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. Eur J Gastroenterol Hepatol. 2017;29(1):48-55. [Crossref]  [PubMed]
70. White mN, Dotan E, Catalano pJ, et al. Advanced pancreatic cancer clinical trials: the continued underrepresentation of older patients. J Geriatric Oncol. 2019;10:540-6. [Crossref]  [PubMed]  [PMC]